Maze Therapeutics Eyes 30% UACR Reduction in MZE829 and >40-Fold MZE782 Biomarker Rise
Maze Therapeutics will report MZE829 APOL1-mediated kidney disease data by quarter-end, targeting a 30% UACR reduction in diabetic and non-diabetic cohorts sized comparably to a previous Vertex study. It plans two Phase 2 trials for SLC6A19 inhibitor MZE782—PKU mid-year and CKD in H2—after >40-fold urinary phenylalanine gains versus rivals.
1. MZE829 Trial Design and Objectives
Maze has guided MZE829 cohort size to mirror a prior Vertex APOL1-mediated kidney disease study, enrolling diabetic and non-diabetic patients. The company remains blinded to interim data and will disclose specific patient numbers and cohort splits at the quarter-end readout.
2. Proof-of-Concept Metrics
Maze defines a 30% reduction in urine albumin-to-creatinine ratio (UACR) from baseline as clinically meaningful proof of concept in broad AMKD. Investigators favor UACR over UPCR in moderate disease, and Maze will report both average and patient-level UACR outcomes.
3. MZE782 Phase 2 Trial Plans
The SLC6A19 inhibitor MZE782 is slated for two Phase 2 studies—phenylketonuria mid-year and chronic kidney disease in the second half—after biomarker data showed a >40-fold urinary phenylalanine rise versus a ~10-fold increase from a competitor.
4. Mechanistic and Recruitment Updates
Maze’s APOL1 program employs dual mechanisms—blocking pore function and disrupting assembly—guided by in vitro and in vivo models. Recruitment remains on track, supported by standard-panel genotyping availability and a new ICD-10 code for APOL1 variants.